OsteoGeneX is committed to leveraging its innovative signaling pathway technologies to discover and develop small molecule therapeutics that are focused primarily on building new bone.

OsteoGeneX was founded to take advantage of its unique insight on the Sclerostin/Wise (Ectodin, Usag-1) family. OsteoGeneX utilizes a novel approach to modulate the activity of Sclerostin/ Wise that ultimately controls the growth of bone. The company is establishing itself as the premier company in this field with its lead platform program in osteoporosis, small molecule anabolic bone therapeutics in preclinical development for the treatment of bone loss.

OsteoGeneX has a world class management & advisory team with a successful track record in discovering, developing, and commercializing novel therapeutics.

Michael Beckloff is President of Beckloff Associates, Inc., Overland Park, Kansas. Founded in 1976, Beckloff Associates, Inc. (BAI), a wholly-owned subsidiary of Cardinal Health, provides a wide range of consulting services required to obtain marketing approval for drugs, biologics and medical devices for the U.S., Canadian and European markets. They have successfully supported worldwide drug development across a broad range of therapeutic categories and have worked with virtually all types of product formulations.

Sam Campbell is President and CEO of CritiTech, Inc. and has over twenty years of experience in managing early stage life science and technology companies. He currently is also the President of Campbell-Becker, Inc., a company that specializes in assisting early stage companies properly organize and finance their growth. He and his associates have provided start-up capital to numerous life science companies and worked with them to develop their company strategy and its implementation.

John P. Harrington is recently retired from 39 years with Johnson & Johnson (J&J) and subsidiaries. He started as director of Quality Assurances, and Director of Industrial Engineering where he developed a strategic operations plan that resulted in saving J&J $5 Million a year. Mr. Harrington spent ten years as VP Operations in J&J Orthopedics, building team based organizations which lead to a tenfold growth in sales. He then became VP Business Development at J&J, where he was responsible for leading successful merger of J&J orthopedics and Codman into J&J Professional Inc, a $300 million company, in addition to other successful acquisitions. Mr. Harrington has international experience in manufacturing, as VP Manufacturing & logistics for Dentsply International, and operations as VP Operations for Depuy Spine.

Bruce W. Jenett is Partner and Co-Chair of the Global Life Sciences Sector at DLA Piper in East Palo Alto, California. Mr. Jenett is a renowned life science lawyer who brings over 25 years of industry experience focused on the representation of domestic and international business and finance clients in the life sciences industry. He received his J.D. from Georgetown University Law Center and a B.A. from Princeton. Mr Jenett is highly experienced in equity and debt financing, licensing and distribution, strategic alliances, joint ventures, and mergers and acquisitions, as well as general counseling issues, representing both start-ups and large multinational corporations. Among his many accomplishments, Mr. Jenett handled one of the largest ag-bio partnering deals in history, as well as one of the largest partnering deals ever done by an Irish venture capital-backed biotechnology company with a major pharmaceutical company. A frequent speaker on corporate and finance issues to both business and attorney audiences, Mr. Jenett is also a member of the Bioethics Committee of BIO, and of the BayBio Board of Directors, and he is a member of, and Co-Chair of the Strategic Planning Committee of, San Francisco Mayor Gavin Newsom’s Biotech Advisory Council.  Chambers & Partners: America’s Leading Lawyers for Business consistently names him one of the leading business lawyers in the United States.

Ken Lynn is currently serving as senior Vice President, Business Development at Newlink Genetics, an oncology-focused immunotherapeutics company based in Ames, Iowa. Prior to Mr. Lynn's NewLink position, he was Executive Vice President - Kansas Technology Enterprise Corporation. Mr. Lynn has over 20 years of biotechnology business and technology development expertise. Early on, he worked as in-house legal counsel for United Telecom Computer Group and then served as Corporate Counsel with Marion Laboratories. Mr. Lynn left Marion to become Vice President and General Counsel of U.S. Bioscience and later joined Cortech, Inc., where he progressed from Vice President of Business Development and General Counsel to Chairman and CEO.

Enrico Picozza is a Venture Partner at HLM Venture Partners and a serial entrepreneur.  He has founded or served as a member of the startup team for several companies that address markets such as diagnostics and regenerative medicine.  In 2000 Enrico was a Founder, COO/CTO and board member for HTS Biosystems,  a systems development company.  Under Enrico's stewardship HTS successfully developed and launched cutting edge products, which are now sold by GE Health Care. Preceding HTS Enrico's entrepreneurial career started at Perkin-Elmer immediately after graduation from the University of Connecticut. Enrico was the first member to join the newly formed Biotechnology group that was responsible for developing and commercialization of the  PCR technology.  After 7 years and 120 million in sales this team became the catalyst  for what is today Applera.  His involvement in the success of PCR was later recognized by the Smithsonian. Today that product has a market value of > 5 billion dollars.  Enrico's experience includes international business,  IP management, research & development, sales and marketing. Market experience includes MDX, forensics, drug discovery, medical devices, proteomics and  emerging markets.    Presently Enrico is interim  CEO to CELTHERA a regenerative medicine company, he also serves as advisor to multiple other young companies, established companies,  venture firms and academic organizations.

Scott Weir is the Director of the Office of Therapeutics, Discovery and Development (OTDD), Kansas University. Dr. Weir’s role is to identify, organize and implement drug discovery and early drug development. Dr. Weir has over 20 years of professional experience in the field of drug discovery and development. At Marion Laboratories, Inc. he was directly involved in the successful registration of several drug products. Furthermore, at Quintiles, Dr. Weir managed an early drug development division which included pharmacology, toxicology, drug metabolism and pharmacokinetics, bioanalytical, and clinical pharmacology services.

Gunda Georg, PhD, is a thought leader in the field of Medicinal Chemistry. Professor Georg is head of the Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota. Prior to her position in Minnesota, she was a Distinguished Professor at the University of Kansas in Lawrence and served as the Director for the Center for Drug Discovery at Higuchi Biosciences Center. The National of Institutes of Health (NIH) identified Georg as one of the top 5% of researchers receiving funding in the last 25 years. She is internationally recognized for her research on discovering and finding potential new drugs to treat cancer. Professor Georg and her group are involved in the design, semi-synthesis, total synthesis, and evaluation of biologically active agents. Professor Georg has served as a review board member of NIH and American Cancer Society review panels.

Debra L. Ellies, Ph.D., CEO, President, & Chairman of the Board of Directors

In July 2006 Dr. Ellies founded OsteoGeneX Inc (OGX), and has worked with the named advisors to develop the unique business strategy for OsteoGeneX Inc. Prior to launching OGX, Dr Ellies was at the Stowers Medical Research Institute in Kansas City, MO. While at the Stowers Institute, Dr. Ellies was a key scientist in the epochal discovery of Sclerostin as a modulator of the WNT pathway. Dr. Ellies was also part of the scientific team which discovered that the CCN family also functioned via WNT signaling. Furthermore, Ellies & Krumlauf were the first to report that Sclerostin blocking antibodies function by blocking Sclerostin action on the WNT pathway. Prior to her work at Stowers, Dr. Ellies conducted basic research on the developmental significance of programmed cell death and managed a laboratory at Ottawa Civic Hospital in Ottawa, Canada. In addition to her remarkable successes in the laboratory, Dr. Ellies co-founded the Brian Ellies Esophageal Cancer Prevention Fund, which works to educate the public and promote awareness of esophageal cancer prevention. Dr. Ellies is the author of several international key scientific manuscripts in the area of signal transduction, and of a number of patents. Dr. Ellies is the Industrial Co-Chair of the Executive Committee and Industrial Co-Director of the Kansas Center for Biomaterials Innovation and Design (KCBID). She received her Ph.D. from Guy’s Hospital London, UK, under the supervision of Prof. Andrew Lumsden, FRS; M.Sc. from University Ottawa, LOEB Research Institute.

William S Rosenberg, M.D., Chief Medical Officer & Chairman of the Scientific Advisory Board

Dr. Rosenberg joined OsteoGeneX in March 2007 as Chief Medical Officer. Dr. William S. Rosenberg, MD, is an innovator in both his practice of medicine and in the development of new technologies and devices in life sciences. Dr. Rosenberg specializes in complex spinal surgery as a neurosurgeon with Midwest Neurosurgery Associates in Kansas City. Prior to joining his current group, he was Director of the Neurospinal Disorders Program at University of California, San Francisco and Co-Founder of the Spine Biomechanics Laboratory at University of California, Berkeley. Dr. Rosenberg received his medical degree from Harvard Medical School and trained in neurosurgery at Massachusetts General Hospital in Boston. In addition to his medical practice, Dr. Rosenberg has served as a consultant for a number of medical device companies in various stages of development and holds several patents for surgical devices and techniques.

Matthew McClorey, J.D., MBA, Chief Financial Officer

Mr. Matthew McClorey is the President and CEO of the Lawrence Regional Technology Center (“LRTC”) where he helps create and grow early stage life sciences and technology companies. Mr. McClorey has consulted with dozens of start-up technology businesses specializing in corporate strategy, operations and early stage capital financing. Since he joined LRTC, the center’s clients have raised over $115,000,000 in seed and early stage capital. Prior to his employment at LRTC, Mr. McClorey was the Vice President of Business Development and Portfolio Management for the Kansas Technology Enterprise Corporation where he managed a multi-million dollar portfolio of debt and equity investments in early stage technology businesses. Mr. McClorey came to KTEC from Deloitte Consulting where he was a senior consultant providing strategy and information technology consulting services to Fortune 1000 companies.

Sigurd Berven, M.D., is Associate Professor in Residence in the Department of Orthopedic Surgery at the University of California, San Francisco. Dr. Berven has a strong clinical interest in spinal disorders of children and adults, in addition to pediatric and adult deformity, degenerative conditions of the spine, spinal tumors and spinal trauma. Berven 's basic science research involves the use of cellular and molecular techniques to study biological regeneration of the spine, including intervertebral discs. He is an invited speaker at national and international conferences. He is a graduate of the Harvard Medical School Combined Orthopedic Residency. After completing his residency, he was a chief resident at in pediatric orthopedic surgery at Boston Children's Hospital, and then studied as a clinical fellow at the UCSF Spinal Disorders Program . Dr. Berven was an undergraduate at Stanford University, a graduate student at Oxford University in philosophy, politics and economics.

Nancy Lane, M.D., is an Endowed Professor of Medicine, Rheumatology and Aging at the University of California, Davis Medical School in Sacramento,California. She is leading investigator in research on osteoporosis having participated in ground breaking studies with parathyroid hormone and the pathobiology of bone fragility. She was the President of the U.S. Bone and Joint Decade Board from 2005-2007, and is on the editorial board of the Journal of Bone and Mineral Research, Osteoporosis International, and Arthritis Research, Nature Clinical Practice Rheumatology and co-editor of Arthritis and Rheumatism. She is also a consultant reviewer for numerous peer-reviewed journals, among them JAMA, Annals of Internal Medicine, and Journal of Bone and Joint Surgery. Dr. Lane is a frequent lecturer on osteoporosis and the author of hundreds of journal articles, book chapters, books such The Osteoporosis Book, a guide for patients and their family, and abstracts.

Harold Rosen, M.D., is the Director of the Osteoporosis Prevention and Treatment Center at Harvard Beth Israel Deaconess Medical Center, which provides state-of-the-art bone densitometry and consultation regarding osteoporosis and other metabolic bone diseases. Dr. Rosen is an endocrinologist specializing in osteoporosis and other metabolic bone diseases, such as the osteomalacia that can occur with celiac disease. Dr. Rosen attended the Albert Einstein College of Medicine and graduated with distinction in research in Endocrinology. He did his Internship in Internal Medicine at Montefiore Hospital and his residency in Internal Medicine at the University of Cincinnati Medical Center. He did fellowships in endocrinology and Geriatrics at Beth Israel Hospital in Boston, and remained there as faculty, doing clinical research in osteoporosis.